Whereas an estimated 3,110,403 men in the United States live with prostate cancer; Whereas, according to the National Cancer Institute, the percentage of newly diagnosed prostate cancer cases in men under 65 has significantly increased and stands at 41.9 percent; Whereas 1 in 9 men in the United States will be diagnosed with prostate cancer in their lifetimes; Whereas prostate cancer is the most commonly diagnosed nonskin cancer and the second-leading cause of cancer-related deaths among men in the United States; Whereas the American Cancer Society estimates that in 2019, 174,650 men will be diagnosed with, and more than 31,620 men will die of, prostate cancer; Whereas the odds of developing prostate cancer rise rapidly after age 50; Whereas African-American men suffer from a prostate cancer incidence rate that is significantly higher than that of White men and have more than double the prostate cancer mortality rate than that of White men; Whereas some veterans are at an increased risk of prostate cancer due to chemical or radiation exposure during military service; Whereas a study conducted at the Portland VA Medical Center and Oregon Health and Science University found that veterans exposed to Agent Orange were at an increased risk for both developing prostate cancer and developing more aggressive forms of the disease; Whereas having a father or brother with prostate cancer more than doubles the risk of a man developing prostate cancer, with a higher risk for men who have a brother with the disease and the highest risk for men with several affected relatives; Whereas screening by a digital rectal examination and a prostate-specific antigen blood test can detect the disease at the earlier, more treatable stages, which could increase the chances of survival for more than 5 years to nearly 100 percent; Whereas prostate cancer is almost always diagnosed with a needle biopsy where the prostate is mapped and tissue cores removed from at least a dozen sites